Quebec Drug-Discovery Consortium Awards $7.2M to Four Public-Private Research Teams

Each team will receive between C$500,000 and C$1 million ($451,000 and $903,000) per year over the next three years to commercialize drug-discovery tools of interest to the Canadian branches of Pfizer, AstraZeneca, and Merck, each of which committed C$4 million over four years to the consortium.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories